Bilaketaren emaitzak - Heinz‐August Horst

  • Erakusten 1 - 16 emaitzak -- 16
Findu emaitzak
  1. 1
    Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma

    Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma nork Christian Hoffmann, Eva Wolf, Gerd Fätkenheuer, Thomas Buhk, Albrecht Stoehr, Andreas Plettenberg, Hans‐Jürgen Stellbrink, Hans Jaeger, Uwe Siebert, Heinz‐August Horst

    Argitaratua 2003
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

    Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials nork Thorsten Raff, Nicola Gökbuget, Silke Lüschen, Regina Reutzel, Matthias Ritgen, Sebastian Irmer, Sebastian Böttcher, Heinz‐August Horst, Michael Kneba, Dieter Hoelzer, Monika Brüggemann

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery

    Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery nork Christian Hoffmann, Susanne Tabrizian, Eva Wolf, Christian Eggers, Albrecht Stoehr, Andreas Plettenberg, Thomas Buhk, Hans‐Jürgen Stellbrink, Heinz‐August Horst, Hans Jäger, Thorsten Rosenkranz

    Argitaratua 2001
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

    Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia nork Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, Anthony S. Stein, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, Monika Brüggemann, Kate Taylor, Noemi Mergen, Albrecht Reichle, Heinz‐August Horst, Violaine Havelange, Max S. Topp, Ralf C. Bargou

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

    Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease nork Christian Hoffmann, Holger Schmid, Markus Müller, Christian Teutsch, Jan van Lunzen, Stefan Eßer, Timo Wolf, Christoph Wyen, Michael Sabranski, Heinz‐August Horst, Stefan Reuter, Martin Vogel, Hans Jäger, Johannes R. Bogner, Keikawus Arastéh

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus‐associated Hodgkin's disease

    Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus‐associated Hodgkin's disease nork Christian Hoffmann, Kai Uwe Chow, Eva Wolf, Gerd Faetkenheuer, Hans‐Juergen Stellbrink, Jan van Lunzen, Hans Jaeger, Albrecht Stoehr, Andreas Plettenberg, Jan‐Christian Wasmuth, Juergen Rockstroh, Franz Mosthaf, Heinz‐August Horst, Hans‐Reinhard Brodt

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

    Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia nork Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, H. Diedrich, Max S. Topp, Monika Brüggemann, Heinz‐August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    <i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

    <i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group nork Verena I. Gaidzik, Peter Paschka, Daniela Späth, Marianne Habdank, Claus‐Henning Köhne, Ulrich Germing, Marie von Lilienfeld‐Toal, Gerhard Held, Heinz‐August Horst, Detlef Haase, Martin Bentz, Katharina S. Götze, Hartmut Döhner, Richard F. Schlenk, Lars Bullinger, Konstanze Döhner

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

    High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation nork Nicola Gökbuget, Nadežda Basara, H. Baurmann, Joachim Beck, Monika Brüggemann, H. Diedrich, B. Güldenzoph, G. Hartung, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Ralph Naumann, Richard Ratei, Albrecht Reichle, Hubert Serve, Matthias Stelljes, Andreas Viardot, Mohammed Wattad, Dieter Hoelzer

    Argitaratua 2011
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy

    Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy nork Inga Nagel, Marius Bartels, Johannes Duell, Hans‐Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver G. Ottmann, Roman Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz‐August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

    Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphobl... nork Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Petra Klappers, Matthias Stelljes, Svenja Neumann, Andreas Viardot, Reinhard Marks, H. Diedrich, Christoph Faul, Albrecht Reichle, Heinz‐August Horst, Monika Brüggemann, Dorothea Wessiepe, Chris Holland, Shilpa Alekar, Noemi Mergen, Hermann Einsele, Dieter Hoelzer, Ralf C. Bargou

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

    Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation nork Nicola Gökbuget, Daniel Stanze, Joachim Beck, H. Diedrich, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Karl‐Anton Kreuzer, Lothar Leimer, Albrecht Reichle, Markus Schaich, Stefan Schwartz, Hubert Serve, Michael Starck, Matthias Stelljes, Reingard Stuhlmann, Andreas Viardot, Knut Wendelin, Mathias Freund, Dieter Hoelzer

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

    Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial nork Dieter Hoelzer, Jan Walewski, Hartmut Döhner, Andreas Viardot, Wolfgang Hiddemann, Karsten Spiekermann, Hubert Serve, Ulrich Dührsen, Andreas Hüttmann, Eckhard Thiel, Jolanta Dengler, Michael Kneba, Markus Schaich, Ingo G.H. Schmidt‐Wolf, Joachim Beck, Bernd Hertenstein, Albrecht Reichle, Katarzyna Domańska‐Czyż, Rainer Fietkau, Heinz‐August Horst, Harald Rieder, Stefan Schwartz, Thomas Burmeister, Nicola Gökbuget

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia nork Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget, Adele K. Fielding, Andre C. Schuh, Josep‐María Ribera, Andrew H. Wei, Hervé Dombret, Robin Foà, Renato Bassan, Önder Arslan, Miguel Á. Sanz, Julie Bergeron, Fatih Demırkan, Ewa Lech‐Marańda, Alessandro Rambaldi, Xavier Thomas, Heinz-August Horst, Monika Brüggemann, Wolfram Klapper, Brent L. Wood, A. Fleishman, Dirk Nagorsen, Christopher P. Holland, Zachary Zimmerman, Max S. Topp

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

    Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD nork Richard F. Schlenk, Daniela Weber, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Thomas Kindler, Michael Lübbert, Dominik Wolf‎, Jörg Westermann, Doris Kraemer, Katharina S. Götze, Heinz‐August Horst, Jürgen Krauter, Michael Girschikofsky, Mark Ringhoffer, Thomas Südhoff, Gerhard Held, Hans-Günter Derigs, Roland Schroers, Richard Greil, Martin Grießhammer, Elisabeth Lange, Alexander Burchardt, Uwe M. Martens, Bernd Hertenstein, Lore Marretta, Michael Heuser, Felicitas Thol, Verena I. Gaidzik, Wolfgang Herr, Julia Krzykalla, Axel Benner, Konstanze Döhner, Arnold Ganser, Peter Paschka, Hartmut Döhner

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

    Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, mult... nork Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Harry P. Erba, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortés, Gail J. Roboz, Olatoyosi Odenike, Xavier Thomas, Violaine Havelange, Johan Maertens, Hans-Günter Derigs, Michael Heuser, Lloyd E. Damon, Bayard L. Powell, Gianluca Gaïdano, Angelo-Michele Carella, Andrew H. Wei, Donna E. Hogge, Adam R. Craig, Judith A. Fox, Renee Ward, Jennifer A. Smith, Gary D Acton, Cyrus R. Mehta, Robert K. Stuart, Hagop M. Kantarjian

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: